RecruitingPhase 1NCT06555744
A Study of ZW191 in Participants With Solid Tumors
A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors
Sponsor
Zymeworks BC Inc.
Enrollment
145 participants
Start Date
Oct 30, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Pathologically or cytologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable), recurrent and/or metastatic disease.
- Measurable disease per RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
- Adequate cardiac function: Cardiac left ventricular function, as defined by left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram (ECHO) or multigated acquisition scan (MUGA).
- Other adequate organ function.
Exclusion Criteria4
- Known additional malignancy that is progressing or requires active treatment or may interfere with study endpoints.
- Has received prior Topoisomerase I inhibitor(TOPO1i) antibody drug conjugate treatment, regardless of washout period.
- Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease.
- Severe chronic or active infections (including known active SARS-CoV-2 infection) requiring systemic therapy, including antibacterial, antifungal, or antiviral therapy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGZW191
Administered intravenously
Locations(27)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06555744
Related Trials
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT0659647354 locations
Study of GS-2426 in Participants With Advanced Solid Tumors
NCT076012432 locations
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT073973386 locations
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT0506728375 locations
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT0679255217 locations